20/20 Onsite’s Post

👀 Read our new article in collaboration with Nature Portfolio: “How to turn a data maze into a goldmine through AI drug positioning” This piece interviews Servier’s Samer El Bawab, as well as Owkin voices Jonas Béal and Anna Gogleva, to explain the science behind our AI drug positioning engine DrugMatch. In it we explores how we use knowledge graphs, the importance of subgroup positioning and what the pharmaceutical industry thinks. Read the article here https://lnkd.in/eGhQgD9r

Insights from DDIF 2024! 🌟 Our LSM students had an incredible opportunity to attend the DDIF Conference – a deep dive into the latest trends and innovations in Drug Discovery and Development! Key takeaways included: 💊Cutting-edge research on new drug targets 💊The future of personalised medicine and precision therapies 💊Global collaboration in pharmaceutical innovation 💊 The role of AI and machine learning in speeding up drug development #LSM #Lifescience #LSMCareer https://bit.ly/2TlVga3

💡We are delighted to share the highlight impressions of the first AI Forum from Pharma to Pharma. 💡 It was a great experience that provided over 70 participants with insights and knowledge from presenters working in pharma. With over 50 companies in attendance, this event marked the beginning of an exciting new chapter in the evolving world of AI in pharma. Together, we created a valuable new platform for discussing topics related to AI in the pharmaceutical industry. This AI - Forum from June 11th, 2024 marks the start of an ongoing exchange. Check out the highlight video to get insights from the forum. Stay tuned for the next AI events to come. #artificialintelligence #pharma #shqa #ffi #aiforum

The landscape of #artificialintelligence is undergoing a seismic shift. The recent AI Forum in Switzerland by shqa swiss health quality association and FFI Ventures, held on June 11th, 2024, brought together over 70 participants from more than 50 companies to explore this transformative era. This gathering wasn't just about discussing AI. It was about navigating the revolutionary impact of generative AI in pharma. Presenters from the industry shared initial insights, illuminating how generative AI has an impact in Pharma and to its stakeholders. The forum marked the dawn of a new era, where AI isn't just a tool, but a collaborative partner in pharmaceutical innovation. We've only scratched the surface of generative AI's potential in pharma. This event is the first step in an ongoing journey of discovery and collaboration. Stay connected for future AI events as we continue to explore this rapidly evolving field. The future of pharma is being rewritten by AI, and we're at the forefront of this exciting transformation. Thanks to @shqa providing such a great platform to discuss the disruptive nature of #genAI.

Are you heading to AAPS in October? Make sure to mark your calendar for Dr. Piet Van Der Graaf’s closing plenary session on AI and AI-Assisted Approaches in Pharmaceutical Discovery and Development. This session is a must-attend for anyone interested in the cutting-edge intersection of AI and drug development.   Why You Should Attend: - Discover how AI is revolutionizing pharma. - Hear real-world AI success stories. - Learn from Piet’s experience in QSAR, virtual screening, PK, and PD. - Explore innovative tools like QSP Designer, IBD, and Codex. - Stay updated on the latest in clinical pharmacology and drug development.   Session Details: 📅Date: Wednesday, October 23 🕒 Time: 4:15 - 5:30 PM MT   We’d love to connect with you at the event, so please stop by booth 2310.   For more details on our presence at AAPS, visit: https://lnkd.in/eMXzA4ZQ   #Pharma #AI #DrugDevelopment #QSP #ClinicalPharmacology #PBPK #Simcyp #Chemaxon #Innovation #Healthcare #AAPS

For this weeks #WhatsUpWednesday, we would like to highlight AAIH Treasurer James Zanewicz, JD, LLM, RTTP, who is moderating the BioTechX EU Panel "AI in Drug Development: From Breakthroughs to Breakdowns" today, October 9th 2024. James, along with panelists Miha Stajdohar, Bruce Press, Martin Akerman, Blanca Baez, Szabolcs Nagy, will explore both the triumphs and the hurdles of implementing AI technology in the pharmaceutical industry, aiming to provide a balanced view of how AI is reshaping drug development. This panel is one you won't want to miss! #AAIH #aitechnology #aidrugdevelopment #drugdevelopment #aiinnovation

A fascinating discussion on the implications of AI in healthcare with Neil Rotherham, Rich Cooper and Julian Minett. 💡 #healthcare #pharmatech #AI #bigdata #medicinesinformation

Artificial Intelligence is transforming the pharmaceutical industry, accelerating drug development, and enabling personalized treatments based on individual genetic profiles. This revolution is reshaping healthcare as we know it. 🚀 In our latest article, we explore the emerging trends and key areas where AI is making a significant impact, from genomics to clinical trials. 💡 🔗 https://lnkd.in/eQYa4Usc 📅 Looking to dive deeper into these advancements? Join us at the AI In Pharma Summit 2025, taking place on February 20-21 in Munich. Connect with industry leaders and innovators as we discuss the latest AI applications in pharma, personalized medicine, and more. Don’t miss this chance to stay at the forefront of pharmaceutical innovation. Register now and be part of the future of healthcare! 👇 #VLPharmaAI #AI #Pharma #PersonalizedMedicine #HealthcareInnovation #AIInPharmaSummit2025 #ClinicalTrials #Genomics #PharmaceuticalIndustry #VonlanthenEvents

Thank you, Frank Kumli, for sharing this exciting report! Generative AI will transform pharmaceutical research and development by strengthening #innovation, offering #cost efficiencies, and speeding the traditionally ponderous research-to-market cycle. Successes and advancements in AI have led to wider adoption, integration, and new applications of the technology in drug development. Notably, pharmaceutical companies' are increasingly using generative AI to facilitate the creation of new molecular structures and drug compounds. AI is also facilitating analysis of #RWD for existing treatments, improving companies' potential to file for additional indications. And traditional pharmaceutical companies now often collaborate with specialist AI-driven pharma-tech companies to build healthcare platforms. ---- OM1, Inc. Polaris, powered by PhenOM™, a digital phenotyping AI platform for personalized medicine and clinical research, optimizes clinical trial recruitment by leveraging real-world data, predicted outcomes, and protocol-tailored phenotypic profiles to identify prospective patients, investigators, and sites. https://lnkd.in/evZGcwdf Full Report: https://lnkd.in/eFE7P88x #innovation #bigdata #rwd #realworlddata #drugdevelopment #pharma #access #marketaccess #heor #patientjourney #healthcare #biopharma #ml #drugdiscovery #clinicaltrials #predictiveanalytics #personalizedmedicine #rwe #realworldoutcomes #realworldevidence

The double-edged sword for #medicalaffairs: increasing impact, higher demand At a minimum, medical affairs teams must: - Gather - Analyze - Disseminate ...data-driven and timely insights. How are #pharma innovators using #AI to optimize this process? In a new white paper from Within3 and Reuters Events Pharma, get insight from leaders at Roche, Spark Therapeutics, Inc., Astellas Pharma, and UCB. https://hubs.la/Q02B3n3S0